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Objectives.To evaluate the cost-eﬀectiveness of etoricoxib (90mg) relative to celecoxib (200/400mg), and the nonselective NSAIDs
naproxen (1000mg) and diclofenac (150mg) in the initial treatment of ankylosing spondylitis in Norway. Methods. A previously
developed Markov state-transition model was used to estimate costs and beneﬁts associated with initiating treatment with the
diﬀerent competing NSAIDs. Eﬃcacy, gastrointestinal and cardiovascular safety, and resource use data were obtained from the
literature. Data from diﬀerent studies were synthesized and translated into direct costs and quality adjusted life years by means of
a Bayesian comprehensive decision modeling approach. Results. Over a 30-year time horizon, etoricoxib is associated with about
0.4 more quality adjusted life years than the other interventions. At 1 year, naproxen is the most cost-saving strategy. However,
etoricoxibiscostandqualityadjustedlifeyearsavingrelativetocelecoxib,aswellasdiclofenacandnaproxenafter5yearsoffollow-
up. For a willingness-to-pay ceiling ratio of 200,000 Norwegian krones per quality adjusted life year, there is a >95% probability
that etoricoxib is the most-cost-eﬀective treatment when a time horizon of 5 or more years is considered. Conclusions.E t o r i c o x i b
is the most cost-eﬀective NSAID for initiating treatment of ankylosing spondylitis in Norway.
1.Introduction
Ankylosing spondylitis (AS) is a chronic inﬂammatory rheu-
matic disease that aﬀects the axial skeleton, causing charac-
teristics inﬂammatory back pain, which can lead to struc-
tural and functional impairments. Asymmetric peripheral
arthritis is present in about 20–40% of patients with AS [1].
In Europe, estimates of prevalence of ankylosing spondylitis
vary by tenfold from 0.08% to 0.86% [2–4]. The direct costs
of AS are substantial. In Europe, the annual total direct costs
per patient have been estimated at C1,800 to C2,800 [5].
The introduction of antitumour necrosis factor alpha (anti-
TNFα) agents has increased the direct cost of AS [6].
The ﬁrst-line treatment of AS is nonsteroidal anti-
inﬂammatory drugs (NSAIDs) [7–9]. Patients with severe
disease refractory to NSAIDs are eligible for anti-TNFα
agents[10].ThenonselectiveNSAIDs(nsNSAIDs)havebeen
associated with an increased risk of gastrointestinal (GI)
adverseeventssuchasulcersandGIbleedingbecauseoftheir
inhibition of the gastroprotective COX-1 isoform. COX-2
selective inhibitors were developed with reduced GI toxicity
when compared with nonselective NSAIDs. Etoricoxib and
celecoxib have been demonstrated to have a superior upper
gastrointestinal (GI) safety proﬁle [11–14]. The MEDAL
(Multinational Etoricoxib and Diclofenac Arthritis Long
Term) program demonstrated the risk of cardiovascular
(CV) events with etoricoxib (60mg/d and 90mg/d) compa-
rable to diclofenac (75mg bid and 50mg tid) [15]. On the
eﬃcacy side, etoricoxib has been shown, at doses of 90mg
and 120mg, to be superior compared to naproxen 1000mg
in the treatment of AS [16]. Celecoxib (200mg and 400mg)
showed comparable eﬃcacy to diclofenac (150mg) [17].2 International Journal of Rheumatology
Given the economic burden of AS, a cost-eﬀectiveness
analysisofinterventionsforASiswarranted.Theobjectiveof
this study was to evaluate the cost-eﬀectiveness of etoricoxib
(90mg) compared to celecoxib (200 and 400mg), diclofenac
(150mg), and naproxen (1000mg) in the treatment of
patients with AS in Norway. Analyses were performed from
the health care perspective.
2. Methods
In the present economic evaluation, a comprehensive deci-
sion Bayesian modelling approach was used which integrates
evidence synthesis and parameter estimation for eﬃcacy and
safety with cost-eﬀectiveness modeling in a single uniﬁed
framework [18].
2.1. Markov Model Description. A previously published
Markov-state transition model was used to estimate the cost-
eﬀectiveness of etoricoxib versus celecoxib and nsNSAIDs
in the treatment of AS patients requiring daily NSAID
treatment [19]. The model consisted of eight health states
reﬂecting treatment received: (1) “initial NSAID” (etori-
coxib, celecoxib, or nsNSAIDs, depending on intervention
arm of the model), (2) “initial NSAID with proton-pump
inhibitor (PPI),” (3) alternative nsNSAIDs with PPI, (4)
alternative nsNSAID with PPI and aspirin, (5) alternative
nsNSAID, (6) anti-TNFα treatment, (7) discontinued anti-
TNFα treatment, and (8) death. All patients start in health
state 1. Transitions from state to state were determined by
lack of treatment eﬃcacy, and the diﬀerent types of events
as presented in Table 1. Figure 1 presents the diﬀerent types
of cost generating GI, CV, and other events relevant to each
Markov cycle.
For each health state, utilities were assigned based on
the Bath Ankylosing Spondylitis Functional Index (BASFI)
and the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) [20]. Over time, BASFI will worsen thereby de-
creasing utilities. Disutilities were assigned based on occur-
rence of adverse events. Drug acquisition costs, and cost due
to adverse events were taken into account.
The model was developed with a cycle length of 1 year.
The model followed individuals for a maximum of 30 cycles
(30 years) as by this time the majority of individuals had
reached the absorbing state (i.e., death).
2.2. Source Data
2.2.1. Eﬃcacy: BASFI, BASDAI, and Discontinuation due
to Lack of Eﬃcacy. The eﬃcacy of etoricoxib, celecoxib,
diclofenac,ornaproxeninASregardingBASFI,BASDAI,and
discontinuation was obtained from a previously performed
systematic review and Bayesian mixed treatment comparison
(MTC) of randomized controlled trials using noninforma-
tive prior distributions [19, 21, 22]. In Table 2 the individual
study results are presented. In Table 3, the results of the MTC
as used in the cost-eﬀectiveness analysis are presented.
For the model analysis, the expected change from base-
line (CFB) estimates for BASFI and BASDAI by treatment
weresubtractedfrombackgroundBASFIandBASDAIvalues
which develop over time. Over time, an increase in BASFI
of 0.5 (scale 0–100) per annum was assumed [6, 20]. It
was assumed that background BASDAI scores remained
stable over time [16, 23, 24]. For patients who continue
responding to treatment, it is assumed that their treatment
eﬀect regarding BASFI and BASDAI (i.e., the CFB scores)
remain constant over time. Patients who switched to another
nsNSAIDs were assumed to have the average treatment eﬀect
of diclofenac and naproxen as obtained from the MTC. For
patients that switched to anti-TNFα, a treatment eﬀect of
23 points and 19 points was used for BASFI and BASDAI,
respectively.
It was assumed that 10% withdraw from anti-TNFα each
year [20, 25]. For patients who withdraw from anti-TNFα
treatment BASDAI, and BASFI measurements revert back to
baseline values as reported by Ara et al. [20].
2.2.2. Safety. An overview of all event-related parameters is
presented in Table 3. Incidence rates of an upper GI perfora-
tion, ulcer, or bleeding (PUB) for etoricoxib, celecoxib, and
the nsNSAIDs were estimated with an indirect comparison
of the relative incidence rates versus placebo as reported by
Ramey et al. (OA, RA, and AS patients) and Silverstein et
al. (OA and RA patients) [11, 14, 19]. Incidence rates for
suspected PUBs were calculated by subtracting the PUBS
from all-investigator-reported PUBs by Ramey et al. [11].
RatesofminorGIsymptomswerebasedondiscontinuations
due to clinical GI events in the MEDAL programme [28].
Except for PUBs, the rates for other upper GI events with
etoricoxib were also used for the celecoxib arm of the model.
T h ep r o b a b i l i t i e so ft r e a t m e n to fG Ie v e n t sw e r eb a s e do n
Moore et al. [29].
The incidence of a thrombotic CV event with etoricoxib,
diclofenac, and naproxen were obtained by performing
an indirect comparison of the results from the MEDAL
programme by Cannon et al. and the relative incidence
rate of etoricoxib versus naproxen from a meta-analysis of
thrombotic CV events in 12 phase II-IV clinical trials [15,
19, 30]. Rates for etoricoxib were also used for the celecoxib
arm of the model. The occurrence of edema, hypertension,
coronary heart failure, hepatic adverse events, and renal
events were obtained from the MEDAL programme as well
[15]. For anti-TNFα treatment, and treatment after anti-
TNFα, no adverse events were taken into consideration.
The adverse event rate for second-line nsNSAID therapy
was assumed to be equal to the average of those obtained for
diclofenac and naproxen, with the exception of the incidence
ofanupperGIeventinapatientreceivingnsNSAIDplusPPI
therapy, which was assumed to be reduced by 40% [29]. The
GI and CV risk for a patient who switched to nsNSAID plus
aspirin and PPI was assumed to be comparable to that for
nsNSAID alone.
2.2.3. Mortality. The case-fatality of a UGI PUB or LGI
Bleed was 3.6% [29, 31]. A 13% case-fatality for a CV
event was used for etoricoxib and celecoxib, and 12.8% case-
fatality for nsNSAIDs [15]. For patients not experiencing GIInternational Journal of Rheumatology 3
Table 1: Transitions between diﬀerent health states of Markov model due to events and lack of eﬃcacy.
To
From Initial NSAID Initial NSAID
with PPI
Alternative
nsNSAID
Alternative
nsNSAID with
PPI
Alternative
nsNSAID with
PPI & aspirin
Anti-TNFα Discontinued
Anti-TNFα
Initial NSAID
(i) No events
(ii) Events w/o
switch
(i) Suspected
PUB
(ii) Minor upper
GI symptoms
(i) Edema,
hypertension,
hepatic, CHF,
renal; all with
switching
treatment
(ii) Lack of
eﬃcacy
Upper GI PUB CV event NA NA
Initial NSAID
with PPI NA
(i) Suspected
PUB
(ii) Minor upper
GI symptoms
(iii) No events
(iv) Events w/o
switch
NA
(i) Upper GI
(ii) PUB Edema,
hypertension,
hepatic, CHF,
renal; all with
switching tx
(iii) Lack of
eﬃcacy
CV event NA NA
Alternative
nsNSAID NA NA
(i) No events
(ii) Events w/o
switch
(i) Suspected
PUB
(ii) Minor upper
GI symptoms
CV event
(i) Upper GI
PUB
(ii) Edema,
hypertension,
hepatic, CHF,
renal; all with
switching
treatment
(iii) Lack of
eﬃcacy
NA
Alternative
nsNSAID with
PPI
NA NA NA
(i) Suspected
PUB
(ii) Minor upper
GI symptoms
(iii) No events
(iv) Events w/o
switch
CV event
(i) Upper GI
PUB
(ii) Edema,
hypertension,
hepatic, CHF,
renal; all with
switching
treatment
(iii) Lack of
eﬃcacy
NA
Alternative
nsNSAID with
PPI & aspirin
NA NA NA NA
Suspected PUB
(i) Minor upper
GI symptoms
(ii) No events
(iii) Events w/o
switch
(i) Upper GI
PUB
(ii) CV event
(iii) Edema,
hypertension,
hepatic, CHF,
renal; all with
switching
treatment
(iv) Lack of
eﬃcacy
NA
Anti-TNFα NA NA NA NA NA Other Lack of
eﬃcacy
Discontinued
anti-TNFα NA NA NA NA NA NA All4 International Journal of Rheumatology
Table 2: Individual studies and results included for mixed treatment comparison of BASFI, BASDAI and discontinuation due to lack of
eﬃcacy.
Placebo Celecoxib Naproxen∗ Etoricoxib Diclofenac∗
200 mg 400 mg 1000 mg 90 mg 150 mg
Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE) Mean (SE)
BASFI
Barkhuizen et al. [26] 2.00 (3.00) −9.00 (0.50) −11.00 (1.00) −16.00 (2.00)
Van der Heijde et al. [16] −4.00 (1.90) −14.60 (1.80) −19.40 (1.80)
Dougados et al. [27] 1.30 (2.03) −11.90 (2.46)
Sieper et al. [17] −8.00 (1.62) −9.00 (1.23) −9.00 (1.45)
BASDAI
Van der Heijde et al. [16] −6.40 (1.90) −23.6 (1.80) −28.60 (1.80)
Sieper et al. [17] −9.90 (1.71) −13.20 (1.40) −14.80 (1.41)
Discontinuation for lack of eﬃcacy and (sample size)
r nrnrnrnrnrn
Barkhuizen et al. [26] 59 156 25 137 23 161 17 157
Van der Heijde et al. [16] 44 93 20 97 8 100
Dougados et al. [27]3 1 7 6 1 8 8 0
∗For mixed treatment comparison of BASDAI, the results of naproxen and diclofenac were considered as the group nsNSAID.
Surgery
Hospitalization
No surgery
Upper GI PUB
Outpatient
GI event
Inpatient
Suspected PUB
Outpatient
N ou p p e rG IP U B
Treatment
No treatment
Adverse event CV event
Edema
Hypertension
Other event
Hepatic
CHF
Renal
M i n o rG Is y m p t o m
Figure 1: Tree structure reﬂecting events resulting in costs and potential changes in treatment (i.e., transitions between health states of the
Markov model).
or CV adverse events, a Norwegian annual age-dependent
mortality was used, as obtained from the life tables for
Norway [32]. For the evaluation, an AS population with
an average age of 45 was assumed (base-case scenario)
[16].
2.2.4. Utilities. Utilities reﬂect the preference for a certain
health state and are measured on 0-1 scale. A value of 1
reﬂects perfect health and 0 represents death. By summa-
rizing the utility value over time, quality adjusted life years
(QALYs)arecreated.LifeyearsweretransformedintoQALYsInternational Journal of Rheumatology 5
using a relation between utility (EQ-5d) and BASFI and
BASDAI as derived by Ara et al. [20]: Utility = 0.923 −
0.004∗BASFI − 0.004∗BASDAI. Utility loss associated with
adverse events was obtained from the literature [29, 33–36].
2.2.5. Costs. Annual drug acquisition costs were calculated
based on the most commonly prescribed drug within a drug
class and obtained from the Norwegian Medicines Agency
(NoMA September 2007). For anti-TNF treatment, annual
costs of etanercept were used. For each type of GI event,
numbers of units of health care resource use were assigned
and respective unit costs applied to all healthcare resources
to calculate the cost per event. The key cost items for GI
events included costs of treatment (drugs and dispensing),
GP consultations, investigations, inpatient days, and surgery.
Costs of thrombotic CV events were weighted according to
rates in the MEDAL study. All costs of adverse events were
limited to the ﬁrst year. Cost for the other adverse events
(i.e., edema, hypertension, hepatic, and renal) were not
takenintoconsideration.Drugcostsrelatedtoadverseevents
were obtained from NoMA (September 2007); costs related
to GP visits were obtained from the Norwegian Medical
Association (July 2007), and inpatient costs related to events
were obtained from the DRG price list [37]. All costs were
expressed in 2007 Norwegian kroner (NOK).
2.3. Estimating Model Outcomes. Given the Markov state-
transition model structure, the source data were combined
and translated into the following outcomes: quality adjusted
life years, drug acquisition costs, costs of adverse events, total
costs, and net monetary beneﬁt (NMB) calculated as QALYs
multiplied with a willingness-to pay ratio (WTP) minus
costs. WTP is the amount that decision makers are willing-
to pay per additional QALY gained. Eﬀects and costs were all
discounted at 4% in the base-case scenario.
Since the model was fully probabilistic, outcomes were
estimated with MCMC simulation using WinBUGS v 1.4.
For each iteration of the model, new parameter values
were sampled from the estimated (posterior) or deﬁned
distributions for eﬃcacy, safety, and costs (see Table 3).
The model was evaluated by averaging output values over
many iterations (i.e., 10.000), allowing uncertainty in model
parameters to be accounted for. For each iteration, the
QALYs and cost accrued for each cycle were calculated for
each of the treatments according to Sonnenberg and Beck
[38]. At the end of each iteration, the cumulative QALYs
and costs over the cycles were obtained by summing the
resultsoverallcycles.Next,theincrementalcost,incremental
QALYs, and incremental cost-eﬀectiveness ratio (ICER =
incremental costs/incremental QALYs) of etoricoxib versus
the other interventions were evaluated. The probability
of cost-eﬀectiveness was expressed with cost-eﬀectiveness
acceptability curves, calculated as the number of iterations
out of the total number of iterations for which the NMB
was greatest for a given treatment out of all 4 treatments.
Furthermore, analysis were performed to identify the impact
of uncertainty in the source data on the uncertainty in the
QALYs, costs, and NMB estimates.
In the base-case scenario, etoricoxib (90mg) was
compared with celecoxib (200mg & 400mg), diclofenac
(150mg), and naproxen (1000mg). In alternative analyses,
the following scenarios were evaluated: (1) celecoxib 200mg
was used instead of celecoxib 200mg/400mg, (2) only GI
events, (3) only CV events, (4) no adverse events, (5) no
discounting on costs and eﬀects, (6) 8% discounting on costs
and eﬀects, (7) stable BASFI over time, and (8) assuming
an age of 20 years, and (9) anti-TNFα costs excluded. For
each scenario uncertainty in input parameters was taken into
consideration, as outlined above.
3. Results
3.1. Base-Case Scenario. In Table 4, the results of the base-
case scenario are presented for 1 year, 5 years, and 30 years
of follow-up. There was more than 98% probability that
etoricoxib resulted in higher expected QALYs than the other
interventions of interest.
Drug costs are expected to be the highest with celecoxib
(200 & 400mg) followed by etoricoxib (90mg). The nsN-
SAIDs result in the lowest drug costs. After 5 years, however,
the lowest drug costs can be expected for the patients for
whom treatment was initiated with etoricoxib due to the
higher probability of staying on initial therapy and not
switching to the far more expensive anti-TNFα treatment.
After 30 years, the diﬀerence favoring etoricoxib was even
greater.
Relative to a patient starting with nsNSAIDs, the costs
due to GI events were lower for a patient starting with
etoricoxib or celecoxib as a result of a reduced risk of
treatment-requiring GI events. After 30 years, the GI-related
costswithetoricoxibwerehigherthanwithcelecoxibbecause
this latter group of patients switched quicker to anti-TNFα,
which is not associated with GI events. Until 5 years, costs
relatedtothromboticCVeventsweresimilarwithetoricoxib,
celecoxib, and diclofenac, and slightly higher than with
naproxen. For the same reason as the GI-related costs,
the CV-related costs with etoricoxib were higher than with
celecoxib and diclofenac at 30 years of followup. Overall,
naproxen resulted in the lowest cost at 1 year; however, at
5 years and beyond, etoricoxib resulted in the lowest direct
costs of the four alternatives; at 5 year, there is a >96%
probability that the lowest costs are obtained with etoricoxib.
This increased to >99% at 30 years.
InTable 5,thediﬀerenceincostsandQALYsofetoricoxib
relative to the other interventions is presented. Given the
more favourable outcomes regarding costs and QALYs with
etoricoxib after 5 years of followup, etoricoxib is considered
aneconomicallydominant intervention. At1year,etoricoxib
is economically dominant over celecoxib. The incremental
cost-utility ratio (ICER) of etoricoxib relative to diclofenac
and naproxen at 1 year was 59,221 NOK and 107,256 NOK,
respectively. In Figure 2, the probability of cost-eﬀectiveness
for the diﬀerent interventions at diﬀerent willingness-to-pay
(WTP) ratios are presented. For a WTP 200,000 NOK per
QALY there is an 85% probability that etoricoxib is the most
cost-eﬀective intervention at 1 year. This increased to more6 International Journal of Rheumatology
Table 3: Parameters (and distributions) for cost-eﬀectiveness evaluation.
Parameter Value
Uncertainty
range/95% credible
interval
Assumed uncertainty
distribution Source
Eﬃcacy
Change from baseline
BASFI
Etoricoxib (90mg) −17.87 −22.16; −13.64
No distribution assumed;
posterior distributions
directly obtained from
mixed treatment
comparison of extracted
data and simultaneously
forwarded into Markov
model. For MTC,
noninformative prior
distributions were used.
Barkhuizen et al. [26];
Van der Heijde et al. [16]
Dougados et al. [27];
Sieper et al. [17]
Celecoxib (200mg) −10.12 −12.34; −7.932
Celecoxib (400mg) −11.8 −14.52; −9.10
Diclofenac −11.51 −15.68; −7.34
Naproxen −14.82 −17.69; −11.98
Change from baseline
BASDAI
Etoricoxib (90mg) −28.53 −32.06; −25.05
Van der Heijde et al. [16];
Sieper et al. [17]
Celecoxib (200mg) −18.47 −24.12; −12.9
Celecoxib (400mg) −21.77 −26.95; −16.51
Diclofenac/naproxen −23.46 −26.96; −19.96
Probability of
discontinuation
Etoricoxib (90mg) 0.063 0.027; 0.117
Celecoxib (200mg) 0.225 0.165; 0.292 Barkhuizen et al. [26]
Celecoxib (400mg) 0.177 0.113; 0.255 Van der Heijde et al. [16]
Diclofenac/naproxen 0.149 0.105; 0.202 Dougados et al. [27]
BASFI without treatment 45 40; 50 Uniform (40, 50) Based on baseline
characteristics of trials
included in MTC (see
Table 1)
BASDAI without treatment 45 40; 50 Uniform (40, 50)
Disease progression
measured using annual
changes in BASFI
0.5 0; 0.10 Uniform (0, 0.10) Kobelt et al. [6];
Ara et al. [20]
BASFI with anti-TNFα 23 20; 26 Uniform (20, 26)
Ara et al. [20] BASDAI with anti-TNFα 19 18; 20 Uniform (18, 20)
BASFI when stopped with
anti-TNFα 55 50; 60 Uniform (50, 60)
BASDAI when stopped
with anti-TNFα 52 47; 57 Uniform (47, 57)
Annual probability of
discontinuation from
anti-TNFα treatment
0.10 0.05; 0.15 Beta (13.2, 118.8) Ara et al. [20]
Safety and treatment
(annual probabilities)
PUBs
Etoricoxib 0.0111 0.0074; 0.0159 No distribution assumed;
posterior distribution
directly obtained from
indirect comparison
analysis of extracted data
and simultaneously
forwarded into Markov
model. For indirect
comparison of safety,
noninformative prior
distributions were used.
Ramey et al. [11];
Silverstein et al. [14]
Celecoxib 0.0134 0.0075; 0.0221
Diclofenac/naproxen 0.0270 0.0216; 0.0334International Journal of Rheumatology 7
Table 3: Continued.
Parameter Value
Uncertainty
range/95% credible
interval
Assumed uncertainty
distribution Source
Suspected PUBs
Etoricoxib 0.0016 0.0000; 0.0061 No distribution assumed;
posterior distribution
directly obtained from
analysis of extracted data
and simultaneously
forwarded into Markov
model. For indirect
comparison of safety,
noninformative prior
distributions were used.
Ramey et al. [11]
Celecoxib 0.0016 0.0000; 0.0061
Diclofenac/naproxen 0.0030 0.0000; 0.0115
Minor GI events
MEDAL study [15]
Etoricoxib/celecoxib 0.0463 0.0420; 0.0506
Diclofenac/naproxen 0.0704 0.0650; 0.0759
PUB risk reduction with
PPI 0.40 — — Moore et al. [29]
Dying from PUB 0.036 — — Ramey et al. [11];
Laine et al. [28]
Hospitalization given PUB 0.21 0.056; 0.358 Uniform (0.056, 0.358)
Bloom et al. [39];
Maetzel et al. [40];
Knill-Jones et al. [41];
Singh and Ramey, [42];
de Pouvourville [43];
J¨ onsson and Haglund, [44];
Gabriel and Matteson, [45],
Smalley et al. [46];
Edelson et al. [47]
Surgery given
hospitalization 0.25 0.12; 0.39 Uniform (0.12, 0.39)
Maetzel et al. [40];
Knill-Jones et al. [41];
J¨ onsson and Haglund, [44];
Gabriel et al. [48];
Johnson et al. [49];
Kong et al. [50]
Inpatient tx given
suspected PUB 0.25 0.18; 0.32 Beta (36.5, 109.5) Maetzel et al. [40]
Treatment given minor GI 1 — — Assumption
Thrombotic CV event rate No distribution assumed;
posterior distribution
directly obtained from
indirect comparison
analysis of extracted data
and simultaneously
forwarded into Markov
model. For indirect
comparison of safety,
noninformative prior
distributions were used.
Etoricoxib 0.0124 0.0111; 0.01381
Cannon et al. [15];
Curtis et al. [30]
Celecoxib 0.0124 0.0111; 0.01381
Diclofenac 0.0131 0.0117; 0.01454
Naproxen 0.0077 0.0039; 0.01381
Death from thrombotic CV
event
Cannon et al. [15]
Etoricoxib/celecoxib 0.13 — —
Diclofenac/naproxen 0.128 — —8 International Journal of Rheumatology
Table 3: Continued.
Parameter Value
Uncertainty
range/95% credible
interval
Assumed uncertainty
distribution Source
Edema
MEDAL [15]
Etoricoxib/celecoxib 0.0106 0.0086; 0.0127 Beta (101.4, 9459.7)
Diclofenac/naproxen 0.0070 0.0054; 0.0088 Beta (64.9, 9165.4)
Hypertension
Etoricoxib/celecoxib 0.0229 0.0200; 0.0260 Beta (218.9, 9342.0)
Diclofenac/naproxen 0.0153 0.0129; 0.0179 Beta (141.2, 9088.8)
Coronary heart failure
Etoricoxib/celecoxib 0.0044 0.0032; 0.0058 Beta (42.1, 9518.9)
Diclofenac/naproxen 0.0026 0.0017; 0.0037 Beta (24.7, 9490.5)
Hepatic events
Etoricoxib/celecoxib 0.0036 0.0025; 0.00489 Beta (34.4, 9526.6)
Diclofenac/naproxen 0.0218 0.0189; 0.0249 Beta (201.2, 9028.8)
Renal events
Etoricoxib/Celecoxib 0.0114 0.0094; 0.0136 Beta (109.0, 9452.0)
Diclofenac/Naproxen 0.0100 0.0081; 0.0120 Beta (92.3, 9137.7)
Utility
Relation between EQ-5d
and BASFI and BASDAI Ara et al. [20]
Constant 0.924 0.890; 0.957 Normal (0.924, 0.0172)
BASFI −0.004 −0.0057; −0.0029 Normal (−0.004, 0.00072)
BASDAI −0.004 −0.0056; −0.0024 Normal (−0.004, 0.00082)
Disutility due to adverse
events (adjusted for
duration)
Surgery for PUB 0.080 0.069; 0.092
Beta distributions
Moore et al. [29]
Inpatient treatment for
PUB 0.062 0.052; 0.072
Outpatient treatment for
PUB 0.051 0.042; 0.060
Inpatient investigation for
suspected PUB 0.062 0.052; 0.072
Outpatient investigation
for suspected PUB 0.025 0.021; 0.030
Minor GI symptoms
requiring treatment 0.015 0.012; 0.019
Minor GI symptoms not
requiring treatment 0.00004 0.00000; 0.00032
Thrombotic CV event 0.294 0.256; 0.331 Moore et al. [29]
Edema 0.020 0.016; 0.024 Revicki [33]
Hypertension 0.001 0.000; 0.002 Stason and Weinstein, [34]
Hepatic 0.055 0.040; 0.072 Nichol et al. [35]
CHF 0.002 0.001; 0.002 Wong et al, [36]
Renal 0.020 0.016; 0.024 Revicki [33]
Costs of events (NOK)
Surgery for PUB 22,904 18,900; 27,300
Inpatient treatment for
PUB 22,904 18,900; 27,300International Journal of Rheumatology 9
Table 3: Continued.
Parameter Value
Uncertainty
range/95% credible
interval
Assumed uncertainty
distribution Source
Outpatient treatment for
PUB 2,231 2,038; 2,437 Gamma distributions Resource use from Jansen
et al. [19]; drug acquisition
costs from NoMA
(September 2007); GP costs
from Norwegian Medical
Association; DRG prices
from ISF 2007 [37];
Inpatient investigation for
suspected PUB 22,295 18,240; 26,700
Outpatient investigation
for suspected PUB 1,297 1,157; 1,445
Minor GI symptoms
requiring treatment 568 507; 636
Thrombotic CV event 95,555 — — NoMA (September 2007);
ISF 2007 [37];
CHF 45,958 — — NoMA (September 2007);
ISF 2007 [37];
Annual drug costs (NOK)
Etoricoxib (90mg) 4,654 — —
NoMA (September 2007)
Celecoxib (200mg) 3,318 — —
Celecoxib (400mg) 6,636 — —
Diclofenac (150mg) 1,588 — —
Naproxen (1000mg) 1,380 — —
PPI (omeprazole) 3,050 — —
Aspirin (75mg) 383 — —
Anti-TNFα tx cost 143,322 — — NoMA (September 2007)
than 96% for WTP of 500,000 NOK and higher. At 5 and 30
years, there is a more than 99% probability that etoricoxib
is the most cost-eﬀective intervention. Figure 3 provides an
overview which of the parameters have the greatest impact
on (uncertainty) in model outcomes.
3.1.1. Alternative Scenarios. When celecoxib 200mg was
used as a comparator instead of celecoxib 200mg & 400mg
combined, etoricoxib was no longer economically dominant
at 1 year. Etoricoxib is 1,322 NOK more expensive. Given the
QALY gain of 0.07, this translates into a cost per QALY of
17,882 NOK, a cost-eﬀective result.
Scenarios where (1) only GI events were included
as adverse events, (2) only CV events were included as
adverse events, (3) no adverse events were included, (4) no
discounting was applied, (5) 8% discounting was applied,
(6) BASFI was assumed to be stable over time, and (7)
assuming an average age of 20 years provided comparable
cost-eﬀectiveness results as the base-case analysis. Only
for the scenario where anti-TNFα costs were set to zero,
etoricoxib was no longer dominant. However, etoricoxib can
still be considered cost-eﬀective, independent of the time
horizon (see Table 6).
4. Discussion
The economic evaluation demonstrated that etoricoxib
(90mg) is an economically superior treatment of AS to
celecoxib(200&400mg),diclofenac(150mg),andnaproxen
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Figure 2: Cost-eﬀectiveness acceptability curves reﬂecting the
probability of cost-eﬀectiveness for etoricoxib, celecoxib (200 &
400mg), diclofenac, and naproxen at a followup of 1 year, 5 years,
and 30 years (base-case scenario).10 International Journal of Rheumatology
Table 4: Estimated eﬀects and costs by treatment (base-case scenario).
Etoricoxib (90mg) Celecoxib (200 & 400mg) Diclofenac (150mg) Naproxen (1000mg)
Estimate 95% CrI Estimate 95% CrI Estimate 95% CrI Estimate 95% CrI
Life years
1y r s 111111111111
5y r s 4.59 4.59 4.60 4.59 4.59 4.60 4.59 4.59 4.59 4.59 4.59 4.60
30 yrs 16.72 16.69 16.76 16.76 16.73 16.79 16.73 16.69 16.76 16.76 16.71 16.80
QALYs
1y r s 0.74 0.66 0.80 0.67 0.59 0.75 0.69 0.61 0.76 0.70 0.62 0.77
5y r s 3.34 3.02 3.64 3.14 2.78 3.48 3.17 2.82 3.50 3.22 2.88 3.54
30 yrs 11.16 9.85 12.42 10.66 9.24 12.04 10.71 9.30 12.08 10.80 9.41 12.15
P (best)2
98.90% at 1 year 0.00% at 1 year 0.13% at 1 year 0.98% at 1 year
98.94% at 5 years 0.00% at 5 years 0.11% at 5 years 0.95% at 5 years
99.96% at 30 years 0.00% at 30 years 0.00% at 30 years 0.04% at 30 years
Treatment
cost (NOK)
1y r s 4,654 4,654 4,654 4,977 4,977 4,977 1,588 1,588 1,588 1,380 1,380 1,380
5y r s 50,020 41,400 62,060 74,940 62,790 89,160 60,250 44,380 80,180 59,030 43,100 79,000
30 yrs 628,200 463,300 823,600 740,500 544,400 971,100 710,400 517,500 937,800 708,900 516,200 936,000
GI event costs
(NOK)
1y r s 109 69 158 124 65 214 236 144 341 236 144 341
5y r s 554 360 784 648 391 977 939 576 1,356 943 579 1,361
30 yrs 1,159 743 1,644 1,069 654 1,579 1,453 873 2,148 1,469 881 2,173
Thrombotic
CV event costs
(NOK)
1y r s 1,148 1,027 1,278 1,148 1,027 1,278 1,208 1,082 1,345 714 360 1,271
5y r s 5,065 4,617 5,542 4,871 4,476 5,289 5,081 4,535 5,672 3,654 2,590 5,309
30 yrs 10,060 8,452 11,650 7,696 6,712 8,756 8,293 6,852 9,920 6,541 4,888 8,833
Other AE
costs (NOK)
1y r s 202 146 268 202 146 268 120 77 171 120 77 171
5y r s 814 612 1,048 723 555 918 502 323 718 504 324 720
30 yrs 1,507 1,098 1,991 1,048 795 1,342 820 513 1,201 828 517 1,214
Total costs
(NOK)
1y r s 6,115 5,974 6,267 6,452 6,300 6,618 3,152 2,981 3,332 2,449 2,073 3,015
5y r s 56,450 47,920 68,450 81,190 69,120 95,230 66,780 51,010 86,440 64,130 48,120 84,220
30 yrs 640,900 476,900 835,600 750,300 554,500 980,800 721,000 528,800 947,700 717,800 526,000 944,700
P (best)2
0.00% at 1 year 0.00% at 1 year 1.15% at 1 year 98.85% at 1 year
85.26% at 5 years 0.00% at 5 years 0.18% at 5 years 14.57% at 5 years
98.92% at 30 years 0.01% at 30 years 0.03% at 30 years 1.04% at 30 years
1All results are discounted, 4.0% for eﬀects and costs.
2Probability that a certain intervention provides best outcomes (i.e., greatest QALYs, lowest costs).
(1000mg) for both QALY gains and cost savings for a time
horizon longer than 5 years. For a 1-year time horizon,
etoricoxib is associated with greater costs than diclofenac
(150mg)andnaproxen(1000mg),butcanstillbeconsidered
cost eﬀective.
In addition to drug acquisition costs for the NSAIDs,
also costs for anti-TNFα treatment after failure on NSAIDs
were taken into consideration. Given the model structure
we opted for, the average duration on any NSAID was
estimated to be 11.2 years (95% CrI 9.0–13.2) for the
patients starting with etoricoxib, 7.8 (6.8–9.0) years with
celecoxib, 8.3 (6.8–10.1) years with diclofenac, and 8.4
(6.9–10.2) yearswithnaproxen.Thesediﬀerencesexplain the
savings regarding drug acquisition observed when initiating
treatment with etoricoxib over the other treatment strategies
observed atthe5,-and30-yeartime horizon. However, whenInternational Journal of Rheumatology 11
Table 5: Cost-eﬀectiveness of etoricoxib relative to other interventions (base-case scenario).
Incremental costs in NOK Incremental QALYs Incremental cost-eﬀectiveness ratio
Estimate 95% CrI Estimate 95% CrI Estimate 95% CrI
1y e a r
Etoricoxib (90mg)
versus celecoxib (200
& 400mg)
−337 −411 −280 0.06 0.03 0.10 Dominant Dominant Dominant
Etoricoxib (90mg)
versus diclofenac
2,964 2,753 3,173 0.05 0.02 0.09 59,221 33,180 184,500
Etoricoxib (90mg)
versus naproxen
3,666 3,109 4,046 0.03 0.01 0.07 107,256 51,320 494,300
5y e a r s
Etoricoxib (90mg)
versus celecoxib (200
& 400mg)
−24,730 −37,730 −11,720 0.20 0.08 0.33 Dominant Dominant Dominant
Etoricoxib (90mg)
versus diclofenac
−10,320 −26,070 2,840 0.17 0.05 0.30 Dominant Dominant Dominant
Etoricoxib (90mg)
versus naproxen
−7,682 −23,540 5,729 0.12 0.02 0.23 Dominant Dominant Dominant
30 years
Etoricoxib (90mg)
versus celecoxib (200
& 400 mg)
−109,400 −198,700 −38,640 0.51 0.25 0.84 Dominant Dominant Dominant
Etoricoxib (90mg)
versus diclofenac
−80,060 −164,800 −13,280 0.45 0.20 0.76 Dominant Dominant Dominant
Etoricoxib (90mg)
versus naproxen
−76,850 −162,100 −9,622 0.36 0.13 0.66 Dominant Dominant Dominant
Table 6: Cost-eﬀectiveness of etoricoxib relative to other interventions when anti-TNFα costs are set to zero.
Incremental costs in NOK Incremental QALYs ICER
Estimate 95% CrI Estimate 95% CrI Estimate 95% CrI
1y e a r
Etoricoxib (90mg)
versus celecoxib (200
& 400mg)
−337 −410 −280 0.06 0.03 0.10 Dominant Dominant Dominant
Etoricoxib (90mg)
versus diclofenac
2,965 2,756 3,173 0.05 0.02 0.09 59,288 33,190 188,200
Etoricoxib (90mg)
versus naproxen
3,663 3,099 4,043 0.03 0.01 0.07 107,074 50,970 488,500
5y e a r s
Etoricoxib (90mg)
versus celecoxib (200
& 400mg)
2,194 426 3,745 0.20 0.08 0.33 10,926 2083 30820
Etoricoxib (90mg)
versus diclofenac
10,560 9,058 11,880 0.17 0.05 0.30 62,411 34650 198400
Etoricoxib (90mg)
versus naproxen
12,370 10,330 14,000 0.12 0.02 0.23 103,083 49220 465100
30 years
Etoricoxib (90mg)
versus celecoxib (200
& 400mg)
15,740 5,398 25,490 0.51 0.25 0.84 31,009 14330 59810
Etoricoxib (90mg)
versus diclofenac
23,910 14,520 32,990 0.45 0.20 0.76 53,181 34020 103800
Etoricoxib (90mg)
versus naproxen
25,660 16,150 34,810 0.36 0.13 0.66 70,825 42830 17090012 International Journal of Rheumatology
the anti-TNFα acquisition costs are taken out of the picture,
etoricoxibisstilleconomicallymorefavorablethancelecoxib,
diclofenac, or naproxen (see Table 6).
For the current economic evaluation, a comprehensive
decision modeling approach was used. With this approach,
an indirect comparison of eﬃcacy and safety estimates
were integrated with cost-eﬀectiveness analysis in a single
framework [18]. The advantage of this approach is that no
assumptions were made regarding the uncertainty distri-
butions used for sensitivity analysis; the Bayesian posterior
uncertainty distributions of the treatment eﬀect and GI
and CV events as obtained from the MTC were directly
propagated through the Markov model. The most important
factor in the cost-eﬀectiveness analysis was the probability of
discontinuation as estimated with the MTC (see Figure 3)
The etoricoxib GI safety data as used in the analysis were
obtained from clinical trials in OA, RA, AS, and chronic
low back pain patients [11]; the celecoxib GI safety data
were obtained from the CLASS study [14]. These data were
assumed applicable for AS. It could be argued that AS
patients are likely younger than the average patient in the GI
meta-analysis and, therefore, have a lower GI risk. However,
ASpatientsoftenreceivehighernsNSAIDdosesthanpatients
with other arthritic conditions, thereby increasing their risk
for GI events. Risk estimates of CV events were based on the
MEDAL programme comparing etoricoxib with diclofenac
among OA and RA patients and a meta-analysis of 12 phase
II-IV clinical trials comparing etoricoxib with naproxen,
among OA, RA, AS, and chronic low back pain patients
[15, 30]. As AS patients are on average younger than patients
in the MEDAL programme and the meta-analysis, it can
be argued that the risk for CV events might have been
overestimated in the model.
In the model, the risk for a second CV event was set to be
the same as before the CV event, assuming that the increased
CVriskduetothehistoryofaCVeventwascounterbalanced
by adding aspirin to the NSAID. However, the history of a
CV event might have a bigger impact than the protective
eﬀect by aspirin, which would imply an underestimation
of the risk of CV events in the model, and, therefore, an
underestimation of the costs due to CV events. The eﬀect
on the diﬀerence in costs, however, would be limited because
the underestimation applies to both treatment initiated with
etoricoxib and nsNSAIDs.
Costs associated with severity of AS (i.e., GP visits,
specialist visits, paramedical visits, hospitalization, technical
examinations, adaptations and aids) were not included in
the analysis. For the UK, Botteman et al. showed that each
incremental change in one unit of BASDAI (0–100 scale) was
estimated to be associated with a direct medical cost increase
according to Cost = £708.45 + £75.00∗BASDAI [51]. For the
Norwegiansituation,nosuchinformationwasavailable.Asa
result,thecostsavingsoftreatmentofAShaveprobablybeen
underestimated, especially for etoricoxib.
This evaluation was performed for the Norwegian local
situation. In general, it is diﬃcult to “transfer” cost-
eﬀectiveness estimates obtained for one country to another,
due to diﬀerences in treatment practices, resource use, and
unit cost data, among other. Although the cost-eﬀectiveness
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Figure 3: Proportion of explained uncertainty in model outcomes
(incremental QALYs, costs, and net-monetary beneﬁt at WTP of
400,000 NOK) by the most relevant variables for the comparison of
etoricoxib(90mg)versuscelecoxib,diclofenac,andnaproxen(base-
case scenario).
ﬁndings in this study were primarily driven by diﬀerences in
eﬃcacy of the compared interventions, the cost-eﬀectiveness
of the diﬀerent NSAIDs for the management of ankylosing
spondylitis in other countries needs to be conﬁrmed with
country-speciﬁc analysis.International Journal of Rheumatology 13
In conclusion, given the underlying assumptions and
current evidence available, this economic evaluation demon-
strated that etoricoxib is a cost-saving and QALY gaining
therapy for AS in Norway from a health care perspective.
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